The drug crizotinib (Xalkori) substantially lengthens the amount of time some patients with advanced lung cancer live without their disease progressing, according to findings from the first large clinical trial to test the targeted therapy.
Initial results from the trial were presented Sunday at the European Society for Medical Oncology Congress (ESMO) in Vienna, Austria. Read more > >
The Honorable Kathleen Sebelius is the 21st secretary of the Department of Health and Human Services, which includes NCI. In a statement marking Breast Cancer Awareness Month, Secretary Sebelius highlights some of the successes and challenges in the fight against the disease while stressing the importance of prevention and early detection.
- President Signs 6-Month Spending Bill
- Congressional Caucus Holds Childhood Cancer Summit
- FDA Approves Ultrasound Imaging System for Dense Breast Tissue
- New Treatment for Advanced Colorectal Cancer Approved
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at email@example.com.